AMT Medical raises €25 million for bypass procedure without open-Heart surgery

A revolution in cardiac surgery: key innovations

The ELANA® Heart Bypass System enables surgeons to perform a highly advanced form of coronary artery bypass grafting (CABG) using arterial rather than venous grafts. This is done through small incisions in the chest, while the heart continues to beat, and without the use of a heart-lung machine. As a result, the risk of stroke and other complications is significantly reduced, and patients recover much faster. This represents a major shift from traditional methods, which require opening the chest, stopping the heart, and involve lengthy recovery times.

The technique uses a specialized clip and an excimer laser to connect blood vessels, eliminating the need for manual suturing. This enables fast, precise, and reliable vessel connections with fewer complications.

Moreover, the system cuts costs by over 50% when used in combination with surgical robots— thanks to shorter operating room times, reduced hospital stays, fewer complications, and a faster learning curve for surgeons compared to traditional bypass surgery.

Next steps

With CE marking expected by 2026 and clinical trials in the U.S. on the horizon, this funding will support:

• Completion of our European first-in-human trial (results late 2025)

• Expansion into robotic-assisted keyhole surgery, partnering with industry leaders
• A future where 1 million patients annually benefit from safer, faster cardiac care

Rutger Tulleken, CEO of AMT Medical, said: “This financing validates our vision to obsolete open-heart bypass. By enabling same-day discharge procedures, we’re not just improving outcomes—we’re rewriting the future of cardiovascular care.”